Maybe - but who cares. Your question implies that this is "temporary". I do not think so. The stock recovers to prices it was pre-FDA approval.... Half of the company's market cap is cash, the pipeline is attributed zero value... and now the data is good for the next generation treatment.
Long may it rise - correctly - to levels seen in Dec 2014.
Target is generally in line with other analysts in market. This is perhaps why the stock has performed positively today (6th April). Hopefully the start of a positive trend as ENTA has been more adversely affected by GILD discount story than its peers.
Sorry, but this will not happen & if so the timeline is one that is so long. ENTA has $135m of cash & the ability to raise - it has at least 2-3 years of cash at present (i.e. today). ABBV has spent $500m on trials for HCV - why would they throw it all away? HCV is a No.2 in their emphasis in the pipeline - ABBV needs and wants it to be successful; equally the healthcare systems want it to be, as they want to mitigate against the GILD monopoly in HCV.
ENTA would like the royalties, but doesn't depend on them.